RE:RE:RE:$tltff The FDA wants an option that has rates better thenPerhaps a silly question, but say for example TLT's product was on the market and a patient knew they had a 70% chance be CR at 90 days, and only a 19% chance of being CR at 360 days. Knowing this could be a potential oucome, would not all patients request to continue to receive this treatment on a continuous basis , such that the likelihood of a return of cancer is unlikely? In other words, in the real would not treatments of TLD1433 provide 70% of all patients a CR for the rest of their lives?